# Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)

> **NCT06603818** · PHASE2 · WITHDRAWN · sponsor: **National Cancer Institute (NCI)**

## Conditions studied

- Microsatellite Stable Metastatic Colorectal Cancer
- Metastatic Colorectal Cancer
- Colorectal Cancer

## Interventions

- **BIOLOGICAL:** Tiragolumab
- **BIOLOGICAL:** Atezolizumab
- **RADIATION:** Stereotactic Body Radiation Therapy (SBRT)

## Key facts

- **NCT ID:** NCT06603818
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2025-08-15
- **Primary completion:** 2025-08-15
- **Final completion:** 2025-08-15
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The trial is closing due to findings from a related study, prompting the sponsor to discontinue development and end this study.
- **Last updated:** 2026-02-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06603818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06603818, "Immunotherapies in Combination With Stereotactic Body Radiation Radiotherapy in Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC)". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06603818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*